Loading clinical trials...
Loading clinical trials...
Importance of Therapeutic Monitoring of Orally Administered Disease-modifying Drugs Used in the Treatment of Multiple Sclerosis
Conditions
Interventions
Measurement of concentrations of orally-used DMDs
Genetic testing
+2 more
Locations
2
Czechia
University of Ostrava
Ostrava, Moravian-Silesian Region, Czechia
University Hospital Ostrava
Ostrava, Moravian-Silesian Region, Czechia
Start Date
June 1, 2024
Primary Completion Date
November 1, 2025
Completion Date
May 1, 2026
Last Updated
January 18, 2024
NCT06276634
NCT07225504
NCT06809192
NCT05359653
NCT07426991
NCT07376772
Lead Sponsor
University Hospital Ostrava
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions